BioSpace News Archive

Bio NC

Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication

Data presented at European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress

June 6, 2020
·
5 min read
Drug Development

AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients

The safety profile of RINVOQ was consistent with previously reported results in rheumatoid arthritis, with no new risks identified

June 6, 2020
·
16 min read
Policy

Advisory - Recall of certain hand sanitizers that may pose health risks

Health Canada is advising Canadians that certain hand sanitizers are being recalled from the market because they contain industrial-grade ethanol that has not been authorized for use in hand sanitizers in Canada.

June 6, 2020
·
3 min read
Genetown

Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis

Updated PIONEER trial data in patients with indolent SM showed response rate of 60% for avapritinib versus 0% for placebo at 24 weeks, with response defined as ≥30% reduction in total symptom score

June 6, 2020
·
12 min read
Policy

Genetron Health Receives FDA Emergency Use Authorization for SARS-CoV-2 RNA Test and Approval for Export by Chinese Authority

Genetron Holdings Limited, a China-based precision oncology company that covers full-cycle cancer care, announced that its independently developed detection kit for the novel coronavirus received Emergency Use Authorization from the U.S. Food and Drug Administration.

June 6, 2020
·
3 min read
Pharm Country

Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile

Celldex Therapeutics, Inc. announced results from the Company’s Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects.

June 6, 2020
·
9 min read
Drug Development

New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks

New Analyses Presented at the European Academy of Allergy and Clinical Immunology Digital Congress

June 6, 2020
·
18 min read
Policy

Statement from the Chief Public Health Officer of Canada on June 6, 2020

In lieu of a daily in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

June 6, 2020
·
2 min read